Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

NCT04073290 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

238

Enrollment

OTHER

Sponsor class

Conditions

Hepatic Encephalopathy
Cirrhosis, Liver
Portal Hypertension
Liver Diseases
Pathological Processes

Interventions

DRUG: Rifaximin 550 milligram Oral Tablet [XIFAXAN]
DRUG: Placebo oral tablet
DRUG: Lactulose 667 milligram/milliliter Oral Solution

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]